Cytotoxic effect of cisplatin with proteasome inhibitor on osteosarcoma cells.
- Author:
Di-sheng YANG
1
;
Gao-shun LI
;
Zhao-ming YE
;
Jie FENG
;
Xiang GAO
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Antineoplastic Agents; pharmacology; Apoptosis; drug effects; Bone Neoplasms; pathology; Cisplatin; pharmacology; Drug Synergism; Oligopeptides; pharmacology; Osteosarcoma; pathology; Rats; Tumor Cells, Cultured
- From: Journal of Zhejiang University. Medical sciences 2005;34(5):395-399
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the cytotoxic effect of cisplatin with proteasome inhibitor on osteosarcoma cells.
METHODSCell survival was tested by MTT, apoptotic morphology was observed by electron microscopy, apoptotic rate was analyzed by flow cytometry, the transcription level of excision repair cross complementation-1 (ERCC-1) was tested by reverse transcription polymerase reaction.
RESULTSCompared with cells treated with cisplatin alone, cells treated with cisplatin and proteasome inhibitor showed a decreased survival rate, more typical apoptotic morphology, higher apoptotic rate [(14.37 +/-2.37)% vs. (50.93 +/-4.84)%, P<0.01)], and lower transcription level of excision repair cross complementation-1.
CONCLUSIONProteasome inhibitor could increase the cytotoxic effect of cisplatin on osteosarcoma cells and promote cisplatin-induced osteosarcoma apoptosis. These effects may be associated with the decreased transcription of excision repair cross complementation-1.
